Profile data is unavailable for this security.
About the company
RaQualia Pharma Inc. is a Japan-based company engaged in the research and development of pharmaceutical products. The Company is mainly engaged in the discovery and research, the preclinical trials and part of clinical trials of drugs, as well as the licensing of developed compounds to pharmaceutical companies. The Company is focused on pain diseases area and intestinal disease area. Its products include EP4 antagonist, cyclooxygenase-2 (COX-2) inhibitory, 5-HT4 portion partial agonist, among others.
- Revenue in JPY (TTM)2.18bn
- Net income in JPY-253.40m
- Incorporated2008
- Employees67.00
- LocationRaQualia Pharma Inc8F, Daiwa Meieki Bldg.1-21-19, Meieki-MinamiNakamura-kuNAGOYA-SHI 450-0003JapanJPN
- Phone+81 524466100
- Fax+81 525650700
- Websitehttps://www.raqualia.com/
More ▼
Mergers & acquisitions
| Acquired company | 4579:TYO since announced | Transaction value |
|---|---|---|
| FIMECS Inc | 3.96% | 29.84m |
Data delayed at least 20 minutes, as of Jul 26 2024 07:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wakamoto Pharmaceutical Co Ltd | 7.74bn | 108.96m | 8.57bn | 274.00 | 78.36 | 0.71 | 16.46 | 1.11 | 3.14 | 3.14 | 222.97 | 346.51 | 0.4971 | 2.09 | 2.57 | 28,242,430.00 | 0.70 | -2.28 | 0.8046 | -2.64 | 46.52 | 51.00 | 1.41 | -3.97 | 3.85 | -- | 0.0083 | -- | -10.65 | -6.35 | -21.19 | -- | 4.93 | -- |
| Solasia Pharma KK | 408.00m | -1.18bn | 8.91bn | 24.00 | -- | 4.10 | -- | 21.84 | -6.96 | -6.96 | 2.40 | 10.01 | 0.1432 | 2.01 | 3.06 | 17,000,000.00 | -41.50 | -48.57 | -53.67 | -58.83 | 51.23 | 71.01 | -289.71 | -300.89 | 1.68 | -400.00 | 0.2327 | -- | -43.50 | 14.18 | 56.36 | -- | -- | -- |
| K Pharma Inc | 500.00m | -221.98m | 9.04bn | 15.00 | -- | 3.15 | -- | 18.08 | -18.94 | -18.94 | 43.04 | 247.43 | 0.2095 | 4.49 | -- | 33,333,330.00 | -9.30 | -- | -9.83 | -- | 91.00 | -- | -44.40 | -- | 42.60 | -- | 0.00 | -- | -- | -- | 166.34 | -- | -- | -- |
| Perseus Proteomics Inc | 100.40m | -1.10bn | 10.08bn | 25.00 | -- | 5.84 | -- | 100.35 | -93.74 | -93.74 | 8.52 | 117.15 | 0.0471 | 3.35 | 8.55 | 4,016,080.00 | -51.85 | -41.34 | -54.94 | -43.43 | 87.33 | 91.72 | -1,100.04 | -891.26 | 12.77 | -- | 0.00 | -- | 6.58 | -18.31 | -40.34 | -- | 60.30 | -- |
| Kohjin Bio Co Ltd | 4.77bn | 384.98m | 10.89bn | 159.00 | 23.08 | 3.20 | 15.90 | 2.28 | 92.30 | 92.30 | 1,122.07 | 666.48 | -- | -- | -- | 30,000,600.00 | -- | -- | -- | -- | 39.44 | -- | 8.07 | -- | 1.14 | -- | 0.4249 | -- | 0.5715 | -- | -53.61 | -- | -- | -- |
| CanBas Co Ltd (Parent) | 0.00 | -1.09bn | 11.63bn | 12.00 | -- | 3.88 | -- | -- | -64.47 | -64.47 | 0.00 | 166.10 | 0.00 | -- | -- | 0.00 | -43.91 | -65.86 | -45.99 | -79.11 | -- | -- | -- | -1,094.10 | -- | -- | 0.00 | -- | -- | -- | -45.41 | -- | -- | -- |
| Oncolys Biopharma Inc | 28.04m | -1.98bn | 12.47bn | 34.00 | -- | 6.88 | -- | 444.67 | -107.77 | -107.77 | 1.52 | 84.14 | 0.0127 | 0.00 | 0.1476 | 824,647.10 | -89.46 | -45.75 | -101.52 | -51.86 | 100.00 | 60.46 | -7,058.44 | -233.66 | 8.82 | -- | 0.1416 | -- | -93.54 | -17.86 | -68.72 | -- | 28.18 | -- |
| ReproCell Inc | 2.43bn | -31.42m | 12.85bn | 96.00 | -- | 1.48 | 2,254.74 | 5.29 | -0.3466 | -0.3466 | 28.34 | 93.45 | 0.2788 | 5.41 | 5.60 | 25,279,340.00 | -0.3609 | -7.35 | -0.3932 | -8.00 | 46.19 | 39.83 | -1.29 | -27.16 | 10.54 | -- | 0.00 | -- | -17.83 | 17.39 | 89.71 | -- | 13.27 | -- |
| Symbio Pharmaceuticals Ltd | 4.64bn | -2.74bn | 13.91bn | 109.00 | -- | 1.94 | -- | 3.00 | -66.88 | -66.88 | 113.80 | 156.38 | 0.5439 | 2.76 | 5.14 | 42,594,130.00 | -32.15 | -19.18 | -35.33 | -23.62 | 78.38 | 65.84 | -59.12 | -24.32 | 10.43 | -- | 0.00 | -- | -44.15 | 7.82 | -266.45 | -- | 42.39 | -- |
| Ohki Healthcare Holdings Co Ltd | 334.66bn | 2.21bn | 14.10bn | 632.00 | 6.24 | 0.491 | 5.63 | 0.0421 | 160.45 | 160.45 | 24,293.96 | 2,040.70 | 2.56 | 13.33 | 4.80 | 529,526,900.00 | 1.63 | 1.85 | 7.07 | 8.42 | 5.14 | 6.16 | 0.6356 | 0.7178 | 0.8922 | -- | 0.1996 | 13.92 | 9.92 | 5.30 | 1.28 | 1.51 | -5.34 | 5.92 |
| RaQualia Pharma Inc | 2.18bn | -253.40m | 14.22bn | 67.00 | -- | 2.37 | -- | 6.52 | -11.72 | -11.72 | 100.79 | 277.21 | 0.247 | 2.76 | 3.03 | 32,526,720.00 | -2.87 | 2.13 | -3.18 | 2.26 | 88.70 | 88.49 | -11.63 | 5.32 | 3.53 | -- | 0.4031 | 0.00 | -34.85 | 20.62 | -144.74 | -- | 0.0967 | -- |
| Stella Pharma Corp | 269.49m | -763.75m | 14.24bn | 44.00 | -- | 5.50 | -- | 52.83 | -24.63 | -24.63 | 8.70 | 76.12 | 0.0661 | 0.0508 | 3.98 | 6,124,796.00 | -18.74 | -22.50 | -21.00 | -24.83 | 80.63 | -- | -283.40 | -488.65 | 5.52 | -1,319.97 | 0.2819 | -- | 17.65 | -- | 1.94 | -- | -5.87 | -- |
| CellSeed Inc | 193.68m | -892.21m | 17.22bn | 35.00 | -- | 7.69 | -- | 88.92 | -29.71 | -29.71 | 6.47 | 64.75 | 0.088 | 1.63 | 7.62 | 5,533,600.00 | -40.53 | -49.69 | -43.83 | -54.55 | 56.58 | 63.66 | -460.67 | -428.62 | 19.14 | -- | 0.0669 | -- | 50.39 | -28.62 | -11.43 | -- | 80.73 | -- |
| Fuso Pharmaceutical Industries Ltd | 55.41bn | 1.38bn | 21.16bn | 1.31k | 14.01 | 0.5219 | 5.91 | 0.3819 | 159.76 | 159.76 | 6,434.77 | 4,290.49 | 0.7474 | 3.12 | 2.43 | 42,392,500.00 | 1.86 | 1.91 | 3.06 | 3.09 | 24.98 | 26.92 | 2.49 | 2.69 | 1.04 | 54.56 | 0.2576 | 41.10 | 8.61 | 3.76 | -14.21 | 9.02 | 9.13 | -2.64 |
Data as of Jul 26 2024. Currency figures normalised to RaQualia Pharma Inc's reporting currency: Japanese Yen JPY
3.43%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Heights Capital Management, Inc.as of 05 Jan 2023 | 625.00k | 2.89% |
| Simplex Asset Management Co., Ltd.as of 04 Jul 2024 | 97.90k | 0.45% |
| SSgA Funds Management, Inc.as of 03 Jul 2024 | 18.10k | 0.08% |
| DFA Australia Ltd.as of 31 May 2023 | 1.72k | 0.01% |
| LGT Capital Partners AG (Investment Management)as of 30 Nov 2023 | 300.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 11 Jul 2024Source: FactSet Research Systems Inc.
